Skip to content
2000
Volume 32, Issue 11
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Introduction

Glioblastoma (GBM), the most aggressive form of primary brain tumor in adults, remains a significant clinical challenge due to its high recurrence and poor prognosis. Characterized by rapid growth, invasiveness, and resistance to therapy, GBM relies on a sophisticated vascular network to sustain its progression. Angiogenesis, the process of forming new blood vessels, is central to meeting the metabolic demands of the tumor. To address this issue, there is a growing consensus on the need for multi-pronged therapeutic strategies that not only inhibit angiogenesis but also disrupt alternative neovascular mechanisms. Promising approaches include combining anti-angiogenic drugs with agents targeting pathways like neurogenic locus notch homolog protein (NOTCH), Wnt, and C-X-C motif chemokine receptor 4 (CXCR4)/stromal cell-derived factor 1 alpha (SDF-1α) to impede vessel co-option, VM, and GSC trans-differentiation.

Methods

The search strategy consisted of using material from the PubMed data, focusing on key terms such as: “angiogenesis”, “glioblastoma”, “glioma”, “oncogenesis”, “anti-VEGF treatment”, “signaling pathways”, “hypoxia”, “vessels”, “resistance”, and “neurosurgery.

Results

Аs a result of the analysis of existing recent studies, GBM exhibits an adaptive capacity to utilize various neovascular mechanisms, including vessel co-option, vasculogenic mimicry (VM), and the trans-differentiation of glioma stem cells (GSCs) into vascular-like structures, to circumvent traditional anti-angiogenic therapies. Initial successes with anti-angiogenic treatments targeting vascular endothelial growth factor (VEGF) showed improvements in progression-free survival. Still, they failed to significantly impact the overall survival due to the tumor's activation of compensatory pathways. Hypoxia, a critical driver of angiogenesis, stabilizes hypoxia-inducible factors (HIF-1α and HIF-2α), which upregulate pro-angiogenic gene expression and facilitate adaptive neovascular responses. These adaptations include vessel co-option, where tumor cells utilize pre-existing vasculature, and VM, where tumor cells form endothelial-like channels independent of typical angiogenesis. Moreover, the role of GSCs in forming new vascular structures through transdifferentiation further complicates treatment, enabling the tumor to maintain its blood supply even when VEGF pathways are blocked.

Discussion

This review highlights the necessity for comprehensive and targeted treatment strategies that encompass the full spectrum of neovascular mechanisms in GBM. Such strategies are crucial for developing more effective therapies that can extend patient survival and improve overall treatment outcomes.

Conclusion

To address the challenge of understanding tumor angiogenesis and ways to inhibit it, there is a growing consensus on the need for multifaceted therapeutic strategies that not only suppress angiogenesis but also disrupt alternative neovascular mechanisms. The most successfull approaches include the use of antiangiogenic drugs in combination with agents targeting pathways such as the neurogenic locus of the notch homolog protein (NOTCH), Wnt, and C-X-C receptor chemokine motif 4 (CXCR4)/stromal cell-derived factor 1 alpha (SDF-1α) aiming to inhibit vessel co-option, VM, and GSC transdifferentiation.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128367551250703122830
2025-07-22
2026-02-28

  • From This Site

    /content/journals/cpd/10.2174/0113816128367551250703122830
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. PerryJ.R. LaperriereN. O’CallaghanC.J. Short-course radiation plus temozolomide in elderly patients with glioblastoma.N. Engl. J. Med.2017376111027103710.1056/NEJMoa1611977 28296618
     [Google Scholar]
  2. StuppR. HegiM.E. MasonW.P. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.Lancet Oncol.200910545946610.1016/S1470‑2045(09)70025‑7 19269895
     [Google Scholar]
  3. StuppR. TaillibertS. KannerA. Effect of tumor-treating fields plus maintenance temozolomide vs. maintenance temozolomide alone on survival in patients with glioblastoma.JAMA2017318232306231610.1001/jama.2017.18718 29260225
     [Google Scholar]
  4. LuganoR. RamachandranM. DimbergA. Tumor angiogenesis: Causes, consequences, challenges and opportunities.Cell. Mol. Life Sci.20207791745177010.1007/s00018‑019‑03351‑7 31690961
     [Google Scholar]
  5. Le RhunE. PreusserM. RothP. Molecular targeted therapy of glioblastoma.Cancer Treat. Rev.20198010189610.1016/j.ctrv.2019.101896 31541850
     [Google Scholar]
  6. WirschingH.G. RothP. WellerM. A vasculature-centric approach to developing novel treatment options for glioblastoma.Expert Opin. Ther. Targets20212528710010.1080/14728222.2021.1881062 33482697
     [Google Scholar]
  7. LiuJ. PiranliogluR. YeF. ShuK. LeiT. NakashimaH. Immunosuppressive cells in oncolytic virotherapy for glioma: Challenges and solutions.Front. Cell. Infect. Microbiol.202313114103410.3389/fcimb.2023.1141034 37234776
     [Google Scholar]
  8. AkanjiM.A. RotimiD. AdeyemiO.S. Hypoxia-inducible factors as an alternative source of treatment strategy for cancer.Oxid. Med. Cell. Longev.2019201911010.1155/2019/8547846 31485300
     [Google Scholar]
  9. ZhangB. ChenY. ShiX. Regulation of branched-chain amino acid metabolism by hypoxia-inducible factor in glioblastoma.Cell. Mol. Life Sci.202178119520610.1007/s00018‑020‑03483‑1 32088728
     [Google Scholar]
  10. ZhangJ. ChenY. QiuX. The vascular delta-like ligand-4 (DLL4)-Notch4 signaling correlates with angiogenesis in primary glioblastoma: An immunohistochemical study.Tumour Biol.20163733797380510.1007/s13277‑015‑4202‑8 26472724
     [Google Scholar]
  11. AnneseT. ErredeM. d’AmatiA. Differential p-glycoprotein/cd31 expression as markers of vascular co-option in primary central nervous system tumors.Diagnostics20221212312010.3390/diagnostics12123120 36553127
     [Google Scholar]
  12. TrepsL. FaureS. ClereN. Vasculogenic mimicry, a complex and devious process favoring tumorigenesis – Interest in making it a therapeutic target.Pharmacol. Ther.202122310780510.1016/j.pharmthera.2021.107805 33465401
     [Google Scholar]
  13. XieJ. TangJ.X. LiY. KongX. WangW. WuH. ATM activation is key in vasculogenic mimicry formation by glioma stem-like cells.Biomed. Environ. Sci.202437883484910.3967/bes2024.127 39198249
     [Google Scholar]
  14. HolstC.B. PedersenH. ObaraE.A.A. Perspective: Targeting VEGF-A and YKL-40 in glioblastoma – Matter matters.Cell Cycle202120770271510.1080/15384101.2021.1901037 33779510
     [Google Scholar]
  15. GimpleR.C. BhargavaS. DixitD. RichJ.N. Glioblastoma stem cells: Lessons from the tumor hierarchy in a lethal cancer.Genes Dev.20193311-1259160910.1101/gad.324301.119 31160393
     [Google Scholar]
  16. WicksE.E. SemenzaG.L. Hypoxia-inducible factors: Cancer progression and clinical translation.J. Clin. Invest.202213211e15983910.1172/JCI159839 35642641
     [Google Scholar]
  17. AhirB.K. EngelhardH.H. LakkaS.S. Tumor development and angiogenesis in adult brain tumor: Glioblastoma.Mol. Neurobiol.20205752461247810.1007/s12035‑020‑01892‑8 32152825
     [Google Scholar]
  18. JafariA. BabajaniA. Abdollahpour-AlitappehM. AhmadiN. Rezaei-TaviraniM. Exosomes and cancer: From molecular mechanisms to clinical applications.Med. Oncol.20213844510.1007/s12032‑021‑01491‑0 33743101
     [Google Scholar]
  19. RenY. HaoP. DuttaB. Hypoxia modulates A431 cellular pathways association to tumor radioresistance and enhanced migration revealed by comprehensive proteomic and functional studies.Mol. Cell. Proteomics201312248549810.1074/mcp.M112.018325 23204318
     [Google Scholar]
  20. KoledovaZ. SumbalJ. RabataA. Fibroblast growth factor 2 protein stability provides decreased dependence on heparin for induction of FGFR signaling and alters ERK signaling dynamics.Front. Cell Dev. Biol.2019733110.3389/fcell.2019.00331 31921844
     [Google Scholar]
  21. PellerinoA. BrunoF. SoffiettiR. RudàR. Antiangiogenic therapy for malignant brain tumors: Does it still matter?Curr. Oncol. Rep.202325777778510.1007/s11912‑023‑01417‑1 37071295
     [Google Scholar]
  22. HongH. ChenF. ZhangY. CaiW. New radiotracers for imaging of vascular targets in angiogenesis-related diseases.Adv. Drug Deliv. Rev.20147622010.1016/j.addr.2014.07.011 25086372
     [Google Scholar]
  23. CaoY. LangerR. FerraraN. Targeting angiogenesis in oncology, ophthalmology and beyond.Nat. Rev. Drug Discov.202322647649510.1038/s41573‑023‑00671‑z 37041221
     [Google Scholar]
  24. KimH.J. JiY.R. LeeY.M. Crosstalk between angiogenesis and immune regulation in the tumor microenvironment.Arch. Pharm. Res.202245640141610.1007/s12272‑022‑01389‑z 35759090
     [Google Scholar]
  25. MazzoneM. DettoriD. Leite de OliveiraR. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization.Cell2009136583985110.1016/j.cell.2009.01.020 19217150
     [Google Scholar]
  26. AndersonN.M. SimonM.C. The tumor microenvironment.Curr. Biol.20203016R921R92510.1016/j.cub.2020.06.081 32810447
     [Google Scholar]
  27. SenguptaS. MondalM. PrasasviK.R. Differentiated glioma cell-derived fibromodulin activates integrin-dependent Notch signaling in endothelial cells to promote tumor angiogenesis and growth.eLife202211e7897210.7554/eLife.78972 35642785
     [Google Scholar]
  28. LudwigN. WhitesideT.L. Potential roles of tumor-derived exosomes in angiogenesis.Expert Opin. Ther. Targets201822540941710.1080/14728222.2018.1464141 29634426
     [Google Scholar]
  29. Pérez-HerreroE. Fernández-MedardeA. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.Eur. J. Pharm. Biopharm.201593527910.1016/j.ejpb.2015.03.018 25813885
     [Google Scholar]
  30. JiangW. HuangY. AnY. KimB.Y.S. Remodeling tumor vasculature to enhance delivery of intermediate-sized nanoparticles.ACS Nano2015998689869610.1021/acsnano.5b02028 26212564
     [Google Scholar]
  31. SemenzaG.L. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology.Annu. Rev. Pathol.201491477110.1146/annurev‑pathol‑012513‑104720 23937437
     [Google Scholar]
  32. TouatM. IdbaihA. SansonM. LigonK.L. Glioblastoma targeted therapy: Updated approaches from recent biological insights.Ann. Oncol.20172871457147210.1093/annonc/mdx106 28863449
     [Google Scholar]
  33. MastriM. RosarioS. TraczA. FrinkR.E. BrekkenR.A. EbosJ.M. The Challenges of modeling drug resistance to antiangiogenic therapy.Curr. Drug Targets201617151747175410.2174/1389450117666151209123544 26648063
     [Google Scholar]
  34. SeanoG. JainR.K. Vessel co-option in glioblastoma: Emerging insights and opportunities.Angiogenesis202023191610.1007/s10456‑019‑09691‑z 31679081
     [Google Scholar]
  35. MalapelleU. RossiA. Emerging angiogenesis inhibitors for non-small cell lung cancer.Expert Opin. Emerg. Drugs2019242718110.1080/14728214.2019.1619696 31092048
     [Google Scholar]
  36. WojtukiewiczM.Z. MysliwiecM. MatuszewskaE. Heterogeneous expression of proangiogenic and coagulation proteins in gliomas of different histopathological grade.Pathol. Oncol. Res.20212760501710.3389/pore.2021.605017 34257567
     [Google Scholar]
  37. RibattiD. PezzellaF. Vascular co-option and other alternative modalities of growth of tumor vasculature in glioblastoma.Front. Oncol.20221287455410.3389/fonc.2022.874554 35433447
     [Google Scholar]
  38. TeuwenL.A. De RooijL.P.M.H. CuypersA. Tumor vessel co-option probed by single-cell analysis.Cell Rep.2021351110925310.1016/j.celrep.2021.109253 34133923
     [Google Scholar]
  39. FalchettiM.L. D’AlessandrisQ.G. PacioniS. Glioblastoma endothelium drives bevacizumab‐induced infiltrative growth via modulation of PLXDC1.Int. J. Cancer201914461331134410.1002/ijc.31983 30414187
     [Google Scholar]
  40. BiJ. ChowdhryS. WuS. ZhangW. MasuiK. MischelP.S. Altered cellular metabolism in gliomas — An emerging landscape of actionable co-dependency targets.Nat. Rev. Cancer2020201577010.1038/s41568‑019‑0226‑5 31806884
     [Google Scholar]
  41. WatkinsS. RobelS. KimbroughI.F. RobertS.M. Ellis-DaviesG. SontheimerH. Disruption of astrocyte–vascular coupling and the blood–brain barrier by invading glioma cells.Nat. Commun.201451419610.1038/ncomms5196 24943270
     [Google Scholar]
  42. RavinR. Suarez-MeadeP. BusseB. Perivascular invasion of primary human glioblastoma cells in organotypic human brain slices: Human cells migrating in human brain.J. Neurooncol.20231641435410.1007/s11060‑023‑04349‑9 37490233
     [Google Scholar]
  43. FerrerV.P. NetoV.M. MentleinR. Glioma infiltration and extracellular matrix: Key players and modulators.Glia20186681542156510.1002/glia.23309 29464861
     [Google Scholar]
  44. KhanF. PangL. DuntermanM. LesniakM.S. HeimbergerA.B. ChenP. Macrophages and microglia in glioblastoma: Heterogeneity, plasticity, and therapy.J. Clin. Invest.20231331e16344610.1172/JCI163446 36594466
     [Google Scholar]
  45. YadavV.N. ZamlerD. BakerG.J. CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study.Oncotarget2016750837018371910.18632/oncotarget.13295 27863376
     [Google Scholar]
  46. GriveauA. SeanoG. SheltonS.J. A glial signature and Wnt7 signaling regulate glioma-vascular interactions and tumor microenvironment.Cancer Cell2018335874889.e710.1016/j.ccell.2018.03.020 29681511
     [Google Scholar]
  47. DonierE. Gomez-SanchezJ.A. Grijota-MartinezC. L1CAM binds ErbB receptors through Ig-like domains coupling cell adhesion and neuregulin signalling.PLoS One201277e4067410.1371/journal.pone.0040674 22815787
     [Google Scholar]
  48. CaspaniE.M. CrossleyP.H. Redondo-GarciaC. MartinezS. Glioblastoma: A pathogenic crosstalk between tumor cells and pericytes.PLoS One201497e10140210.1371/journal.pone.0101402 25032689
     [Google Scholar]
  49. BurgettM.E. LathiaJ.D. RothP. Direct contact with perivascular tumor cells enhances integrin αvβ3 signaling and migration of endothelial cells.Oncotarget2016728438524386710.18632/oncotarget.9700 27270311
     [Google Scholar]
  50. KruscheB. OttoneC. ClementsM.P. EphrinB2 drives perivascular invasion and proliferation of glioblastoma stem-like cells.eLife20165e1484510.7554/eLife.14845 27350048
     [Google Scholar]
  51. JungE. OsswaldM. RatliffM. Tumor cell plasticity, heterogeneity, and resistance in crucial microenvironmental niches in glioma.Nat. Commun.2021121101410.1038/s41467‑021‑21117‑3 33579922
     [Google Scholar]
  52. KuczynskiE.A. ReynoldsA.R. Vessel co-option and resistance to anti-angiogenic therapy.Angiogenesis2020231557410.1007/s10456‑019‑09698‑6 31865479
     [Google Scholar]
  53. VoutouriC. KirkpatrickN.D. ChungE. Experimental and computational analyses reveal dynamics of tumor vessel cooption and optimal treatment strategies.Proc. Natl. Acad. Sci. USA201911672662267110.1073/pnas.1818322116 30700544
     [Google Scholar]
  54. NolanD.J. CiarrocchiA. MellickA.S. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization.Genes Dev.200721121546155810.1101/gad.436307 17575055
     [Google Scholar]
  55. BuccarelliM. CastellaniG. Ricci-VitianiL. Glioblastoma-specific strategies of vascularization: Implications in anti-angiogenic therapy resistance.J. Pers. Med.20221210162510.3390/jpm12101625 36294763
     [Google Scholar]
  56. KaurB. KhwajaF.W. SeversonE.A. MathenyS.L. BratD.J. Van MeirE.G. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis.Neuro-oncol.20057213415310.1215/S1152851704001115 15831232
     [Google Scholar]
  57. TsengD. Vasquez-MedranoD.A. BrownJ.M. Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas.Br. J. Cancer2011104121805180910.1038/bjc.2011.169 21587260
     [Google Scholar]
  58. PiaoY. LiangJ. HolmesL. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.Neuro-oncol.201214111379139210.1093/neuonc/nos158 22965162
     [Google Scholar]
  59. AhnG.O. BrownJ.M. Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature.Angiogenesis200912215916410.1007/s10456‑009‑9135‑7 19221886
     [Google Scholar]
  60. WakedA. CrabbéM. NeirinckxV. Preclinical evaluation of CXCR4 peptides for targeted radionuclide therapy in glioblastoma.EJNMMI Radiopharm. Chem.2024915210.1186/s41181‑024‑00282‑y 39008219
     [Google Scholar]
  61. GagnerJ.P. SarfrazY. OrtenziV. Multifaceted C-X-C chemokine receptor 4 (CXCR4) inhibition interferes with anti-vascular endothelial growth factor therapy-induced glioma dissemination.Am. J. Pathol.201718792080209410.1016/j.ajpath.2017.04.020 28734730
     [Google Scholar]
  62. BaoS. DarvishiM. AminA.H. CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment.J. Cancer Res. Clin. Oncol.2023149107945796810.1007/s00432‑022‑04444‑w 36905421
     [Google Scholar]
  63. SchonbergD.L. LubelskiD. MillerT.E. RichJ.N. Brain tumor stem cells: Molecular characteristics and their impact on therapy.Mol. Aspects Med.2014398210110.1016/j.mam.2013.06.004 23831316
     [Google Scholar]
  64. JhaveriN. ChenT.C. HofmanF.M. Tumor vasculature and glioma stem cells: Contributions to glioma progression.Cancer Lett.2016380254555110.1016/j.canlet.2014.12.028 25527451
     [Google Scholar]
  65. ZhengZ.Q. ChenJ.T. ZhengM.C. Nestin+/CD31+ cells in the hypoxic perivascular niche regulate glioblastoma chemoresistance by upregulating JAG1 and DLL4.Neuro-oncol.202123690591910.1093/neuonc/noaa265 33249476
     [Google Scholar]
  66. PiccirilloS.G.M. CombiR. CajolaL. Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution.Oncogene200928151807181110.1038/onc.2009.27 19287454
     [Google Scholar]
  67. ChroscinskiD. SampeyD. MaheraliN. Registered report: Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells.eLife20154e0436310.7554/eLife.04363 25714925
     [Google Scholar]
  68. MeiX. ChenY.S. ChenF.R. XiS.Y. ChenZ.P. Glioblastoma stem cell differentiation into endothelial cells evidenced through live-cell imaging.Neuro-oncol.20171981109111810.1093/neuonc/nox016 28340100
     [Google Scholar]
  69. JinZ. ZhanT. TaoJ. MicroRNA - 34a induces transdifferentiation of glioma stem cells into vascular endothelial cells by targeting Notch pathway.Biosci. Biotechnol. Biochem.201781101899190710.1080/09168451.2017.1364965 28859546
     [Google Scholar]
  70. CuiC. ChenX. LiuY. β1,4-Galactosyltransferase V activates Notch1 signaling in glioma stem-like cells and promotes their transdifferentiation into endothelial cells.J. Biol. Chem.201829362219223010.1074/jbc.RA117.000682 29269413
     [Google Scholar]
  71. HuB. WangQ. WangY.A. Epigenetic activation of WNT5A drives glioblastoma stem cell differentiation and invasive growth.Cell2016167512811295.e1810.1016/j.cell.2016.10.039 27863244
     [Google Scholar]
  72. HanX. WangQ. FangS. P4HA1 regulates CD31 via COL6A1 in the transition of glioblastoma stem-like cells to tumor endothelioid cells.Front. Oncol.20221283651110.3389/fonc.2022.836511 35494018
     [Google Scholar]
  73. GuichetP.O. GuelfiS. TeigellM. Notch1 stimulation induces a vascularization switch with pericyte-like cell differentiation of glioblastoma stem cells.Stem Cells2015331213410.1002/stem.1767 24898819
     [Google Scholar]
  74. GarginiR Segura-CollarB HerránzB The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas.Sci Transl Med202012527eaax150110.1126/scitranslmed.aax1501 31969485
     [Google Scholar]
  75. Segura-CollarB. Garranzo-AsensioM. HerranzB. Tumor-derived pericytes driven by EGFR mutations govern the vascular and immune microenvironment of gliomas.Cancer Res.20218182142215610.1158/0008‑5472.CAN‑20‑3558 33593822
     [Google Scholar]
  76. SanvoranartT. SupokawejA. KheolamaiP. Targeting Netrin-1 in glioblastoma stem-like cells inhibits growth, invasion, and angiogenesis.Tumour Biol.20163711149491496010.1007/s13277‑016‑5314‑5 27651158
     [Google Scholar]
  77. LuoQ. WangJ. ZhaoW. Vasculogenic mimicry in carcinogenesis and clinical applications.J. Hematol. Oncol.20201311910.1186/s13045‑020‑00858‑6 32169087
     [Google Scholar]
  78. SabazadeS. GillV. HerrspiegelC. StålhammarG. Vasculogenic mimicry correlates to presenting symptoms and mortality in uveal melanoma.J. Cancer Res. Clin. Oncol.2022148358759710.1007/s00432‑021‑03851‑9 34775516
     [Google Scholar]
  79. SteiM.M. LoefflerK.U. HolzF.G. HerwigM.C. Animal models of uveal melanoma: Methods, applicability, and limitations.BioMed Res. Int.201620161910.1155/2016/4521807 27366747
     [Google Scholar]
  80. CiH. XuZ. XuJ. WangY. WuS. Expressions of KAI1 and E-cadherin in nonsmall cell lung cancer and their correlation with vasculogenic mimicry.Medicine20189740e1229310.1097/MD.0000000000012293 30290593
     [Google Scholar]
  81. ShirakawaK. KobayashiH. HeikeY. Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft.Cancer Res.2002622560566 11809710
     [Google Scholar]
  82. KobayashiH. ShirakawaK. KawamotoS. Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast-enhanced dynamic MRI with the macromolecular contrast agent G6-(1B4M-Gd)(256).Cancer Res.2002623860866 11830544
     [Google Scholar]
  83. ZhangS. LiM. GuY. Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma.J. Exp. Clin. Cancer Res.20082716010.1186/1756‑9966‑27‑60 18983651
     [Google Scholar]
  84. WeiX. ChenY. JiangX. Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments.Mol. Cancer2021201710.1186/s12943‑020‑01288‑1 33397409
     [Google Scholar]
  85. WangS. YuL. LingG. Vasculogenic mimicry and its clinical significance in medulloblastoma.Cancer Biol. Ther.201213534134810.4161/cbt.19108 22258034
     [Google Scholar]
  86. WangN. JainR.K. BatchelorT.T. New directions in anti-angiogenic therapy for glioblastoma.Neurotherapeutics201714232133210.1007/s13311‑016‑0510‑y 28083806
     [Google Scholar]
  87. ChiaoM.T. YangY.C. ChengW.Y. ShenC.C. KoJ.L. CD133+ glioblastoma stem-like cells induce vascular mimicry in vivo.Curr. Neurovasc. Res.20118321021910.2174/156720211796558023 21675958
     [Google Scholar]
  88. ScullyS. FrancesconeR. FaibishM. Transdifferentiation of glioblastoma stem-like cells into mural cells drives vasculogenic mimicry in glioblastomas.J. Neurosci.20123237129501296010.1523/JNEUROSCI.2017‑12.2012 22973019
     [Google Scholar]
  89. MaoX. XueX. WangL. CDH5 is specifically activated in glioblastoma stemlike cells and contributes to vasculogenic mimicry induced by hypoxia.Neuro-oncol.201315786587910.1093/neuonc/not029 23645533
     [Google Scholar]
  90. LiJ. KeY. HuangM. HuangS. LiangY. Inhibitory effects of B-cell lymphoma 2 on the vasculogenic mimicry of hypoxic human glioma cells.Exp. Ther. Med.20159397798110.3892/etm.2014.2162 25667663
     [Google Scholar]
  91. LiuX. WangJ.H. LiS. Histone deacetylase 3 expression correlates with vasculogenic mimicry through the phosphoinositide3‐kinase/ERK– MMP –laminin5γ2 signaling pathway.Cancer Sci.2015106785786610.1111/cas.12684 25940092
     [Google Scholar]
  92. GaoY. YuH. LiuY. Long non-coding RNA HOXA-AS2 regulates malignant glioma behaviors and vasculogenic mimicry formation via the MiR-373/EGFR axis.Cell. Physiol. Biochem.201845113114710.1159/000486253 29310118
     [Google Scholar]
  93. LingG. JiQ. YeW. MaD. WangY. Epithelial-mesenchymal transition regulated by p38/MAPK signaling pathways participates in vasculogenic mimicry formation in SHG44 cells transfected with TGF-β cDNA loaded lentivirus in vitro and in vivo.Int. J. Oncol.20164962387239810.3892/ijo.2016.3724 27748800
     [Google Scholar]
  94. ZhangC. ChenW. ZhangX. Galunisertib inhibits glioma vasculogenic mimicry formation induced by astrocytes.Sci. Rep.2016612305610.1038/srep23056 26976322
     [Google Scholar]
  95. WuN. ZhaoX. LiuM. Role of microRNA-26b in glioma development and its mediated regulation on EphA2.PLoS One201161e1626410.1371/journal.pone.0016264 21264258
     [Google Scholar]
  96. KimH. WonY. ShimJ. KimH. KimB. HongH. Role of EphA2 PI3K signaling in vasculogenic mimicry induced by cancer associated fibroblasts in gastric cancer cells.Oncol. Lett.20191833031303810.3892/ol.2019.10677 31452781
     [Google Scholar]
  97. Brantley-SiedersD.M. CaughronJ. HicksD. PozziA. RuizJ.C. ChenJ. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation.J. Cell Sci.2004117102037204910.1242/jcs.01061 15054110
     [Google Scholar]
  98. GuoX. XuS. GaoX. Macrophage migration inhibitory factor promotes vasculogenic mimicry formation induced by hypoxia via CXCR4/AKT/EMT pathway in human glioblastoma cells.Oncotarget2017846803588037210.18632/oncotarget.18673 29113309
     [Google Scholar]
  99. LiuY. LiF. YangY.T. IGFBP2 promotes vasculogenic mimicry formation via regulating CD144 and MMP2 expression in glioma.Oncogene201938111815183110.1038/s41388‑018‑0525‑4 30368528
     [Google Scholar]
  100. HuangM. KeY. SunX. Mammalian target of rapamycin signaling is involved in the vasculogenic mimicry of glioma via hypoxia-inducible factor-1α.Oncol. Rep.20143251973198010.3892/or.2014.3454 25175735
     [Google Scholar]
  101. VerdugoE. PuertoI. MedinaM.Á. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment.Cancer Commun. (Lond.)202242111083111110.1002/cac2.12361
     [Google Scholar]
  102. RongX. HuangB. QiuS. LiX. HeL. PengY. Tumor-associated macrophages induce vasculogenic mimicry of glioblastoma multiforme through cyclooxygenase-2 activation.Oncotarget2016751839768398610.18632/oncotarget.6930 27824617
     [Google Scholar]
  103. YaoX. PingY. LiuY. Vascular endothelial growth factor receptor 2 (VEGFR-2) plays a key role in vasculogenic mimicry formation, neovascularization and tumor initiation by Glioma stem-like cells.PLoS One201383e5718810.1371/journal.pone.0057188 23536763
     [Google Scholar]
  104. AngaraK. BorinT.F. RashidM.H. Corrigendum to “CXCR2-expressing tumor cells drive vascular mimicry in antiangiogenic therapy-resistant glioblastoma”.Neoplasia201921115615710.1016/j.neo.2018.11.001 30595360
     [Google Scholar]
  105. AngaraK. BorinT.F. ArbabA.S. Vascular Mimicry: A novel neovascularization mechanism driving anti-angiogenic therapy (AAT) resistance in glioblastoma.Transl. Oncol.201710465066010.1016/j.tranon.2017.04.007 28668763
     [Google Scholar]
  106. SongY. MuL. HanX. MicroRNA-9 inhibits vasculogenic mimicry of glioma cell lines by suppressing Stathmin expression.J. Neurooncol.2013115338139010.1007/s11060‑013‑1245‑9 24043603
     [Google Scholar]
  107. XueH. GaoX. XuS. MicroRNA-Let-7f reduces the vasculogenic mimicry of human glioma cells by regulating periostin-dependent migration.Oncol. Rep.20163531771177710.3892/or.2016.4548 26750768
     [Google Scholar]
  108. XuS. ZhangJ. XueH. MicroRNA-584-3p reduces the vasculogenic mimicry of human glioma cells by regulating hypoxia-induced ROCK1 dependent stress fiber formation.Neoplasma2017641132110.4149/neo_2017_102 27881000
     [Google Scholar]
  109. LiH. WangD. YiB. SUMOylation of IGF2BP2 promotes vasculogenic mimicry of glioma via regulating OIP5-AS1/miR-495-3p axis.Int. J. Biol. Sci.202117112912293010.7150/ijbs.58035 34345216
     [Google Scholar]
  110. YinT. WuJ. HuY. ZhangM. HeJ. Long non‐coding RNA HULC stimulates the epithelial–mesenchymal transition process and vasculogenic mimicry in human glioblastoma.Cancer Med.202110155270528210.1002/cam4.4083 34213079
     [Google Scholar]
  111. YuS. RuanX. LiuX. HNRNPD interacts with ZHX2 regulating the vasculogenic mimicry formation of glioma cells via linc00707/miR-651-3p/SP2 axis.Cell Death Dis.202112215310.1038/s41419‑021‑03432‑1 33542193
     [Google Scholar]
  112. ZhangZ. GuoX. GuoX. MicroRNA-29a-3p delivery via exosomes derived from engineered human mesenchymal stem cells exerts tumour suppressive effects by inhibiting migration and vasculogenic mimicry in glioma.Aging20211345055506810.18632/aging.202424 33535172
     [Google Scholar]
  113. RosińskaS. GavardJ. Tumor vessels fuel the fire in glioblastoma.Int. J. Mol. Sci.20212212651410.3390/ijms22126514 34204510
     [Google Scholar]
  114. AngaraK. RashidM.H. ShankarA. Vascular mimicry in glioblastoma following anti-angiogenic and anti-20-HETE therapies.Histol. Histopathol.201732991792810.14670/HH‑11‑856 27990624
     [Google Scholar]
  115. WuH.B. YangS. WengH.Y. Autophagy-induced KDR/] VEGFR-2 activation promotes the formation of vasculogenic mimicry by glioma stem cells.Autophagy20171391528154210.1080/15548627.2017.1336277 28812437
     [Google Scholar]
  116. XueW. DuX. WuH. Aberrant glioblastoma neovascularization patterns and their correlation with DCE-MRI-derived parameters following temozolomide and bevacizumab treatment.Sci. Rep.2017711389410.1038/s41598‑017‑14341‑9 29066764
     [Google Scholar]
  117. BernsenH. van der LaakJ. KüstersB. van der VenA. WesselingP. Gliomatosis cerebri: Quantitative proof of vessel recruitment by cooptation instead of angiogenesis.J. Neurosurg.2005103470270610.3171/jns.2005.103.4.0702 16266053
     [Google Scholar]
  118. MosteiroA. PedrosaL. FerrésA. DiaoD. SierraÀ. GonzálezJ.J. The vascular microenvironment in glioblastoma: A comprehensive review.Biomedicines2022106128510.3390/biomedicines10061285 35740307
     [Google Scholar]
  119. RubensteinJ.L. KimJ. OzawaT. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption.Neoplasia20002430631410.1038/sj.neo.7900102 11005565
     [Google Scholar]
  120. KloepperJ. RiedemannL. AmoozgarZ. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.Proc. Natl. Acad. Sci. USA2016113164476448110.1073/pnas.1525360113 27044098
     [Google Scholar]
  121. ScholzA. HarterP.N. CremerS. Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma.EMBO Mol. Med.201681395710.15252/emmm.201505505 26666269
     [Google Scholar]
  122. PetersonT.E. KirkpatrickN.D. HuangY. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.Proc. Natl. Acad. Sci. USA2016113164470447510.1073/pnas.1525349113 27044097
     [Google Scholar]
  123. QianC. LiuC. LiuW. ZhouR. ZhaoL. Targeting vascular normalization: A promising strategy to improve immune-vascular crosstalk in cancer immunotherapy.Front. Immunol.202314129153010.3389/fimmu.2023.1291530 38193080
     [Google Scholar]
  124. TakanoS. Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation.Brain Tumor Pathol.2012292738610.1007/s10014‑011‑0077‑6 22218709
     [Google Scholar]
  125. Carrera-AguadoI. Marcos-ZazoL. Carrancio-SalánP. Guerra-PaesE. Sánchez-JuanesF. Muñoz-FélixJ.M. The inhibition of vessel co-option as an emerging strategy for cancer therapy.Int. J. Mol. Sci.202425292110.3390/ijms25020921 38255995
     [Google Scholar]
  126. ZhangJ. XueW. XuK. Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: Insights from protein expression profiling and MRI.Theranostics202010167245725910.7150/thno.44427 32641990
     [Google Scholar]
  127. PiaoY. LiangJ. HolmesL. HenryV. SulmanE. de GrootJ.F. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition.Clin. Cancer Res.201319164392440310.1158/1078‑0432.CCR‑12‑1557 23804423
     [Google Scholar]
  128. HuveldtD. Lewis-TuffinL.J. CarlsonB.L. Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion.PLoS One201382e5650510.1371/journal.pone.0056505 23457577
     [Google Scholar]
  129. di TomasoE. SnuderlM. KamounW.S. Glioblastoma recurrence after cediranib therapy in patients: Lack of “rebound” revascularization as mode of escape.Cancer Res.2011711192810.1158/0008‑5472.CAN‑10‑2602 21199795
     [Google Scholar]
  130. RennerD.N. MaloC.S. JinF. ParneyI.F. PavelkoK.D. JohnsonA.J. Improved treatment efficacy of antiangiogenic therapy when combined with picornavirus vaccination in the GL261 glioma model.Neurotherapeutics201613122623610.1007/s13311‑015‑0407‑1 26620211
     [Google Scholar]
  131. ZhaoP. AnamiY. GaoP. Enhanced anti-angiogenetic effect of transferrin receptor-mediated delivery of VEGF-trap in a glioblastoma mouse model.MAbs2022141205726910.1080/19420862.2022.2057269 35388745
     [Google Scholar]
  132. WenP.Y. DrappatzJ. de GrootJ. Phase II study of cabozantinib in patients with progressive glioblastoma: Subset analysis of patients naive to antiangiogenic therapy.Neuro-oncol.201820224925810.1093/neuonc/nox154 29016998
     [Google Scholar]
  133. HainsworthJ.D. BeckerK.P. MekhailT. Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).J. Neurooncol.2019144230331110.1007/s11060‑019‑03227‑7 31392595
     [Google Scholar]
  134. KaleyT.J. PanageasK.S. MellinghoffI.K. Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.J. Neurooncol.2019144240340710.1007/s11060‑019‑03243‑7 31325145
     [Google Scholar]
  135. BrennerA.J. FloydJ. FichtelL. Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma.Sci. Rep.2021111230610.1038/s41598‑021‑81841‑0 33504881
     [Google Scholar]
  136. LiuT. MaW. XuH. PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma.Nat. Commun.201891343910.1038/s41467‑018‑05982‑z 30150753
     [Google Scholar]
  137. PlatetN. LiuS.Y. AtifiM.E. Influence of oxygen tension on CD133 phenotype in human glioma cell cultures.Cancer Lett.2007258228629010.1016/j.canlet.2007.09.012 17977646
     [Google Scholar]
  138. LiZ. BaoS. WuQ. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.Cancer Cell200915650151310.1016/j.ccr.2009.03.018 19477429
     [Google Scholar]
/content/journals/cpd/10.2174/0113816128367551250703122830
Loading
Angiogenesis and Resistance Mechanisms in Glioblastoma: Targeting Alternative Vascularization Pathways to Overcome Therapy Resistance
Curr. Pharm. Des. 32, 811 (2026); https://doi.org/10.2174/0113816128367551250703122830
/content/journals/cpd/10.2174/0113816128367551250703122830
/content/journals/cpd/10.2174/0113816128367551250703122830
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): angiogenesis; Glioblastoma; glioma stem cells; hypoxia; neovascularization; therapy resistance; vasculogenic mimicry; vessel co-option

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test